gcs-100
Small moleculeexperimental
Clinical trial activity
8 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2007 (NCT00514696)
Timeline
Indications
Mechanism of action
- Galectin-3ANTAGONIST
LGALS3 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gcs-100
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02312050 | Phase 2 | Mar 1, 2015 | La Jolla Pharmaceutical Company |
| NCT02333955 | Phase 2 | Jan 1, 2015 | La Jolla Pharmaceutical Company |
| NCT02155673 | Phase 2 | Jan 1, 2014 | La Jolla Pharmaceutical Company |
| NCT01843790 | Phase 2 | Jun 1, 2013 | La Jolla Pharmaceutical Company |
| NCT01717248 | Phase 1 | Jan 1, 2013 | California Institute of Renal Research, Inc., Denver Nephrologists, P.C., La Jolla Pharmaceutical Company, Southwest Clinical Research Institute, LLC |
| NCT00776802 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2008 | La Jolla Pharmaceutical Company, University of California, Los Angeles |
| NCT00609817 | Phase 1 | May 1, 2008 | Harvard University, La Jolla Pharmaceutical Company |
| NCT00514696 | Phase 2 | Feb 1, 2007 | La Jolla Pharmaceutical Company, US Oncology |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| La Jolla Pharmaceutical Company | For profit | 8 | 8 | 2 | 2007 |
| California Institute of Renal Research, Inc. | For profit | 1 | 0 | 1 | 2013 |
| Denver Nephrologists, P.C. | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Southwest Clinical Research Institute, LLC | For profit | 1 | 0 | 1 | 2013 |
| University of California, Los Angeles | Academic/Hospital | 1 | 0 | 1 | 2008 |
| US Oncology | For profit | 1 | 0 | 1 | 2007 |
7 organizations
Page 1 / 1